Grounded in the “inflammation–fibrosis” paradigm and the mechanistic framework of pyroptosis, this study aims to elucidate the molecular pathways linking IL-17/NLRP3-mediated hepatocyte pyroptosis to HSC activation, thus revealing potential therapeutic targets for treating arsenic-related hepatic fibrosis. Here, NLRP3 is linked to Hepatic fibrosis.